Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11778347 | 0.78 | MAPK1 (0.69) | MAPK1POLBKDM4ESMN1; SMN2LMNA | |
| SCHEMBL11776322 | 0.78 | MAPK1 (0.51) | MAPK1POLBSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL16199152 | 0.77 | RAB9A (0.41) | MAPK1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL18839755 | 0.75 | MAPK1 (0.44) | MAPK1KDM4ERAB9ASMN1; SMN2LMNA | |
| SCHEMBL9881652 | 0.74 | MAPK1 (0.45) | MAPK1KDM4ELMNAALDH1A1KMT2A | |
| SCHEMBL6169210 | 0.74 | MAPK1 (0.45) | MAPK1KDM4ESMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL18839913 | 0.74 | MAPK1 (0.47) | MAPK1KDM4ERAB9ASMN1; SMN2LMNA | |
| SCHEMBL5954845 | 0.72 | CYP19A1 (0.60) | MAPK1POLBRAB9ASMN1; SMN2LMNA | |
| SCHEMBL6580348 | 0.72 | MAPK1 (0.47) | MAPK1KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL9920433 | 0.72 | MAPK1 (0.44) | MAPK1SMN1; SMN2LMNAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981999-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981999-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170362260-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362260-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-21 | — | — | US | disclosed |
| US-9683002-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9683002-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160090393-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160090393-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-31 | — | — | US | disclosed |
| US-20150119571-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-04-30 | — | — | US | disclosed |
| US-20150119571-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-04-30 | — | — | US | disclosed |
| US-8871792-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871792-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119571-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MAPK1 1308/4885POLB 3232/4885KDM4E 1265/4885 |
| US-20160090393-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MAPK1 1308/4885POLB 3232/4885KDM4E 1265/4885 |
| US-20170362260-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MAPK1 1308/4885POLB 3232/4885KDM4E 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.